{
    "2018-11-27": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Why Celgene's Blockbuster Cancer Drug Looks Safe â€” For Now",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Blockbuster",
                        "Cancer Drug",
                        "Safe"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Dow Analyst Moves: JNJ",
                "features": {
                    "keywords": [
                        "Dow",
                        "Analyst",
                        "JNJ"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Novartis's Alcon sees myopia epidemic driving sales growth",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Alcon",
                        "myopia",
                        "sales growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "ophthalmology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-12",
                "original_text": "Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "GSK",
                        "J&J",
                        "HIV Drug",
                        "Juluca",
                        "Approval",
                        "Japan"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-05",
                "original_text": "3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "GSK",
                        "Stock",
                        "Up",
                        "Year"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-18",
                "original_text": "Noteworthy ETF Inflows: IWD, JPM, XOM, JNJ",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflows",
                        "IWD",
                        "JPM",
                        "XOM",
                        "JNJ"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "energy",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-25",
                "original_text": "The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Boeing",
                        "Microsoft",
                        "Johnson & Johnson",
                        "Chevron",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "aerospace",
                        "technology",
                        "healthcare",
                        "energy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-10",
                "original_text": "AMAG's Label Expansion of Lead Products Raises Share Price",
                "features": {
                    "keywords": [
                        "AMAG",
                        "Label Expansion",
                        "Lead Products",
                        "Share Price"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}